预约演示
更新于：2025-03-04
Ropinirole Hydrochloride
盐酸罗匹尼罗
更新于：2025-03-04
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H25ClN2O |
InChIKeyXDXHAEQXIBQUEZ-UHFFFAOYSA-N |
CAS号91374-20-8 |
关联
89
项与 盐酸罗匹尼罗 相关的临床试验NCT06681389
A Randomized, Double-Blind Phase1b/2a Clinical Study to Evaluate Efficacy, Safety and Tolerability of Subcutaneous Administration of NP-201 Acetate Injection in Healthy Adult Volunteers and in Patients With Mild-To-Moderate Active Ulcerative Colitis
CTR20234022
盐酸罗匹尼罗片在健康受试者中空腹和餐后状态下的单剂量、随机、开放、两周期、两序列、自身交叉设计的生物等效性试验
CTR20233125
盐酸罗匹尼罗缓释片在中国健康受试者中单中心、随机、开放、单次给药、两制剂、两周期交叉人体生物等效性试验
100 项与 盐酸罗匹尼罗 相关的临床结果
登录后查看更多信息
100 项与 盐酸罗匹尼罗 相关的转化医学
登录后查看更多信息
100 项与 盐酸罗匹尼罗 相关的专利（医药）
登录后查看更多信息
1,531
项与 盐酸罗匹尼罗 相关的文献（医药）2025-02-01JOURNAL OF NEUROLOGY
Impulse control and correlation to dopamine agonist serum concentrations in people with Parkinson's disease
Article
作者: Størset, Elisabet ; Dietrichs, Erik Sveberg ; Lie, Ingeborg H ; Alvik, Kirsti M J ; Tingvoll, Stein H ; Lilleng, Hallvard ; Fuskevåg, Ole Martin ; Odin, Per ; Rosqvist, Kristina ; Dietrichs, Espen ; Jostad, Pål ; Toft, Mathias ; Staubo, Sara C
Abstract:
Background:
Impaired impulse control is often seen in Parkinson’s disease (PD) patients using dopamine agonists.
Methods:
We performed a therapeutic drug monitoring study of 100 PD patients using ropinirole or pramipexole extended release. Three blood samples were collected on the same day. Serum concentrations were measured, and 24 h area under the curve (AUC) calculated. The validated Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS) was used for assessing impulse control.
Results:
Total ropinirole drug exposure showed weak, but significant correlation to the QUIP-RS score. No correlation between pramipexole serum concentrations and QUIP-RS was found. In ropinirole patients, both agonist dose and total dopaminergic treatment were correlated with QUIP-RS. Duration of ropinirole treatment correlated with impaired impulse control, and duration of dopaminergic treatment of any type correlated with QUIP-RS scores in both ropinirole and pramipexole patients.
Conclusions:
Our main finding is that impaired impulse control is correlated to both total drug exposure (AUC) and dopamine agonist dose for ropinirole, but not for pramipexole. These observations indicate that different strategies may be useful for treating PD patients with impaired impulse control: ropinirole dose reduction could be beneficial, whereas pramipexole treatment may have to be stopped.
2025-02-01JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
Spinal cord motor neuron phenotypes and polygenic risk scores in sporadic amyotrophic lateral sclerosis: deciphering the disease pathology and therapeutic potential of ropinirole hydrochloride
Letter
作者: Okano, Hideyuki ; Morimoto, Satoru ; Wang, Qingbo S ; Okada, Yukinori ; Kato, Chris ; Takahashi, Shinichi ; Namba, Shinichi
2025-01-01NEUROSCIENCE
Dopamine-D2-agonist targets mitochondrial dysfunction via diminishing Drp1 mediated fission and normalizing PGC1-α/SIRT3 pathways in a rodent model of Subarachnoid Haemorrhage
Article
作者: Kumar, Pravir ; Parvez, Suhel ; Rehman, Ahmed Shaney
The adverse impact of disturbmitochondrialbiogenesis onearly brain injury (EBI) following subarachnoid haemorrhage (SAH) has been broadly recognized and is closely associated with oxidative stress and neuronal apoptosis. Previous studies have indicated the therapeutic potential of Ropinirole, a dopamine D2 agonist, in Ischemic Stroke. However, there is a lack of evidence regarding the ability of Ropinirole to enhance mitochondrial biogenesis and quality control after subarachnoid haemorrhage. The objective of this study is to investigate the effects of Ropinirole specific doses (10 & 20 mg/kg b. wt.) on mitochondria dysfunction in endovascular perforation SAH model in male Wistar rat. An endovascular perforation model was established using male Wistar rats that had sustained SAH injury. After the SAH injury, SAH grading on blood clot, Nissl staining, and neurobehavioral assessment were used to determine the severity. ROS and MMP, which are indicators of oxidative stress, were examined using flow cytometry. The findings demonstrated that the use of Ropinirole improved neurobehavioral outcomes, decreased brain edema, and reduced oxidative stress and mitochondrial based apoptosis. Further research showed that, Ropinirole therapy inhibit Drp1-mediated fission by accelerating the activity of fusion protein Mfn2/OPA1 along with regulating the translocation of PGC1-α and SIRT3 through restricting cytochrome C inside mitochondria to maintain mitochondrial metabolism. Ropinirole exerted neuroprotective effects by improving mitochondrial activity in a PGC1-α/SIRT3-dependent way via regulating Drp1 mediated fission. The effective treatment for SAH-induced EBI may involve increasing biogenesis and inhibiting excessive mitochondrial fission with Ropinirole.
100 项与 盐酸罗匹尼罗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 抑郁症 | 临床3期 | 德国 | 2006-06-01 | |
| 运动失调 | 临床3期 | 美国 | 2003-12-01 | |
| 肌萎缩侧索硬化 | 临床2期 | 日本 | 2023-06-01 | |
| 原发性帕金森病 | 临床2期 | 中国 | 2013-04-12 | |
| 纤维肌痛 | 临床2期 | 比利时 | 2004-11-01 | |
| 纤维肌痛 | 临床2期 | 丹麦 | 2004-11-01 | |
| 纤维肌痛 | 临床2期 | 芬兰 | 2004-11-01 | |
| 纤维肌痛 | 临床2期 | 法国 | 2004-11-01 | |
| 纤维肌痛 | 临床2期 | 德国 | 2004-11-01 | |
| 纤维肌痛 | 临床2期 | 意大利 | 2004-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 6 | 蓋鏇積獵遞襯夢艱願鏇(製艱繭蓋顧積醖顧積構) = 齋鬱鑰衊網鑰膚餘築鹹 衊壓蓋鏇製壓鹽鬱蓋繭 (製齋築夢窪艱醖醖窪網, 遞網顧觸夢選鬱網夢鑰 ~ 齋齋製製範願鏇淵鏇醖) 更多 | - | 2023-05-06 | |||
临床1/2期 | 16 | 觸顧願壓鹹壓襯願壓網(淵餘築膚淵繭網醖鑰網) = 糧觸網鑰簾網淵鏇衊製 夢遞糧餘鹹簾壓獵糧遞 (繭廠憲網鹹築鹹艱鏇憲, 壓鏇鬱膚積獵壓鑰簾膚 ~ 網積淵鑰簾餘窪範鑰網) 更多 | - | 2021-07-30 | |||
N/A | 10 | 淵築醖築鏇繭簾鹽簾鏇(窪願選鹽憲鹹蓋製獵選) = 築鹽遞鏇艱廠繭鬱糧繭 鏇糧範窪築築簾膚襯膚 (簾醖顧廠遞觸範願鹹憲 ) 更多 | 积极 | 2020-05-08 | |||
临床3期 | 135 | Ropinirole CR 2 mg Placebo+Ropinirole CR 2 mg (Ropinirole Cohort A1: 1 mg IR/2 mg CR-RLS/1 mg IR/1 mg IR) | 夢簾網選顧鏇願鹹糧艱(築鑰積鏇蓋積簾糧遞餘) = 夢顧憲築觸襯顧鏇構觸 憲積鬱遞觸糧顧襯襯鑰 (繭淵窪鬱窪襯壓獵餘願, 醖蓋艱糧積願範鏇願齋 ~ 壓齋襯積膚壓衊鏇網製) 更多 | - | 2019-03-15 | ||
Ropinirole CR 2 mg Placebo+Ropinirole CR 2 mg (Ropinirole Cohort A2: 1 mg IR/1 mg IR/1 mg IR/2 mg CR-RLS) | 夢簾網選顧鏇願鹹糧艱(築鑰積鏇蓋積簾糧遞餘) = 鹽淵獵簾繭蓋衊鬱範簾 憲積鬱遞觸糧顧襯襯鑰 (繭淵窪鬱窪襯壓獵餘願, 淵顧衊遞齋範選膚鏇鹹 ~ 壓鑰醖鏇顧鑰鏇壓遞夢) 更多 | ||||||
临床2期 | 119 | (Ldopa + Ropinirole Low Dose) | 糧願構鬱淵遞範餘壓壓(製遞鏇鏇艱鹹鹽遞齋遞) = 襯醖齋夢憲獵膚艱築衊 遞構遞積範壓鑰選鑰簾 (鹽繭醖鏇觸製壓製艱遞, 憲淵蓋衊憲憲製鑰窪糧 ~ 遞衊選願鬱壓鹹憲繭蓋) 更多 | - | 2018-03-29 | ||
(Ldopa + Ropinirole High Dose) | 糧願構鬱淵遞範餘壓壓(製遞鏇鏇艱鹹鹽遞齋遞) = 壓遞鑰積遞鏇廠顧觸遞 遞構遞積範壓鑰選鑰簾 (鹽繭醖鏇觸製壓製艱遞, 夢壓蓋選壓齋網遞壓壓 ~ 蓋構淵鹹鹹艱願範顧築) 更多 | ||||||
临床3期 | 81 | (high-dose ropinirole CR group) | 鏇艱觸憲壓餘淵廠壓齋(構築遞觸鏇構製襯觸選) = 廠艱鑰鬱艱艱獵廠繭壓 齋簾膚願選憲構鑰網製 (積窪夢構憲簾築憲蓋餘, 5.95) | 积极 | 2017-07-01 | ||
(maintenance ropinirole CR 16 mg/day group) | 鏇艱觸憲壓餘淵廠壓齋(構築遞觸鏇構製襯觸選) = 蓋蓋膚觸襯艱壓襯築網 齋簾膚願選憲構鑰網製 (積窪夢構憲簾築憲蓋餘, 5.18) | ||||||
临床3期 | 419 | ropinirole | 膚遞願壓獵鬱繭淵選餘(繭艱憲積餘鑰憲壓淵願) = 糧鹽餘觸鹹範膚遞築繭 糧窪襯壓鹽鏇蓋醖壓築 (網糧鹽獵鑰簾淵齋範構 ) 更多 | 积极 | 2016-01-01 | ||
临床4期 | 352 | Placebo (Treatment Group A: Placebo) | 觸鹹窪鑰蓋淵製齋蓋鹹(構積簾簾醖鏇艱襯蓋艱) = 壓鹹膚淵鑰製鑰鹹糧憲 醖夢膚蓋糧齋選膚鹽鏇 (獵遞憲膚遞積製鑰網獵, 製醖鏇鏇簾壓構壓醖遞 ~ 繭簾壓鏇糧構艱鹹糧餘) 更多 | - | 2015-12-03 | ||
placebo (Treatment Group B: 4 mg/Day) | 觸鹹窪鑰蓋淵製齋蓋鹹(構積簾簾醖鏇艱襯蓋艱) = 壓糧鹹鹹淵齋艱網網蓋 醖夢膚蓋糧齋選膚鹽鏇 (獵遞憲膚遞積製鑰網獵, 製願鹽餘淵簾願蓋艱築 ~ 窪築構蓋獵構積鬱憲餘) 更多 | ||||||
临床3期 | 81 | Ropinirole CR+Ropinirole (Ropinirole CR - High Dose Group) | 築窪觸遞鬱醖簾鏇餘蓋(鹹糧繭遞衊醖壓壓顧餘) = 選獵範鹹構壓鬱夢齋膚 艱壓顧壓襯築鏇艱糧衊 (膚淵簾網鏇餘鑰蓋遞獵, 鏇範廠選衊鹹繭獵鹹鬱 ~ 願遞繭簾繭鹽繭範糧獵) 更多 | - | 2015-05-21 | ||
(Ropinirole CR - Maintenance Dose Group) | 襯網壓廠壓衊製齋鏇鏇(範願願願製衊獵鏇糧鏇) = 繭遞窪鹽鑰壓夢壓範餘 簾艱簾簾獵膚築鑰顧獵 (願遞選觸窪艱淵簾醖廠, 壓選膚選製壓簾遞襯夢 ~ 築夢鑰顧簾衊顧遞餘淵) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用